Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Bladder-sparing approaches in muscle-invasive urothelial carcinoma

Richard Cathomas • 5 Jun 2022
ASCO 2022
Bladder Cancer Genitourinary Cancer

Richard Cathomas, MD, PhD, Hospital Graubünden, Chur, Switzerland, highlights the importance of bladder-sparing approaches in advanced muscle-invasive bladder cancer as well as other areas of unmet needs in this patient population. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Richard Cathomas

0:35
EV-302: 1L enfortumab vedotin in combination with pembrolizumab
Richard Cathomas • 5 Jun 2022
0:46
UC highlights at ASCO 2022
Richard Cathomas • 5 Jun 2022
1:18
Primary analysis of SAKK 06/17: perioperative chemoimmunotherapy with durvalumab for operable MIUC
Richard Cathomas • 5 Jun 2022
2:34
First-line treatments for patients with mHSPC and mCRPC
Richard Cathomas • 27 Sep 2021

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals